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Abstract
Objective—To compare population versus customized fetal growth norms in identifying
neonates at risk for adverse outcomes (APO) associated with small for gestational age (SGA).
Study Design—Secondary analysis of an intrapartum fetal pulse oximetry trial in nulliparous
women at term. Birthweight percentiles were calculated using ethnicity- & gender-specific
population norms and customized norms (Gardosi).
Results—508 (9.9%) and 584 (11.3%) neonates were SGA by population (SGApop) and
customized (SGAcust) norms. SGApop infants were significantly associated with a composite
adverse neonatal outcome, neonatal intensive care admission, low fetal oxygen saturation and
reduced risk of cesarean delivery; while both SGApop and SGAcust were associated with a 5-
minute Apgar score < 4. The ability of customized and population birthweight percentiles in
predicting APO was poor (12 out of 14 APOs had AUC <0.6).
Conclusion—In this intrapartum cohort, neither customized nor normalized-population norms
adequately identify neonates at risk of APO related to SGA.
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Introduction
Disturbances in fetal growth are associated with increased neonatal and infant morbidities as
well as adverse long term health consequences.(1–5) Fetal growth is determined by a
combination of genetic, environmental, physiologic and pathologic influences. Traditionally,
evaluation of fetal growth has been accomplished by comparing fetal or neonatal weight to
population based norms. (6, 7) These population norms are usually derived from either
heterogeneous or highly-selected patient cohorts that included abnormally grown fetuses
(whether large or small), and fail to account for individual variability. Relying on these
norms can lead to misclassification of growth e.g. pathologic fetal growth restriction versus
constitutionally small but otherwise healthy fetus. (8,9)
In order to circumvent these limitations with population-based standards, a number of
customized norms have been developed. Customized norms model the optimal fetal growth
in an uncomplicated pregnancy by accounting for individual variables that are known to
affect growth. They allow the measurement of deviation from an ideal fetal growth potential
rather than deviation from an expected norm for a population, and thus are thought to be a
better predictor of adverse perinatal outcomes. (9) One of the more widely used models is
that of Gardosi et al. (10–13) Using large datasets of normal pregnancies, Gardosi and
colleagues developed a model that determines the optimal growth of each fetus using
specific maternal and fetal characteristics. This model has been shown to better detect
disturbances in fetal growth. (8–11) The association between abnormal fetal growth by
customized growth potential and adverse perinatal outcomes has been validated in various
studies from different countries (UK, Sweden, New Zealand, Australia, and others). (9, 13)
Recently, using a large US cohort, Gardosi et al determined the coefficients for the
customized growth model for the US population and then internally validated, in the same
database used to develop the coefficients, the association between small for gestational age
(SGA) status by the customized model and adverse perinatal and neonatal outcomes (APO).
(12, 14)
The ability of the Gardosi model for the US population to predict APO associated with SGA
has not been validated in a patient cohort that is independent from the one from which the
model was derived. Additionally its usefulness in an intrapartum setting has not been
verified. Therefore, our aims in this study are to test our hypotheses that smallness for
gestational age is associated with APO and that a customized fetal growth norm compared
with a normalized-population standard better identifies these APOs; and consequently
externally validate the Gardosi model for the US population using an intrapartum cohort.
Materials & Methods
Study Design
This was a secondary analysis of the Eunice Kennedy Shriver National Institute of Child
Health and Human Development Maternal-Fetal Medicine Units Network multicenter
randomized trial of intrapartum fetal pulse oximetry conducted between May 2002 and
February 2005 in 14 US centers. (15) Nulliparous women who had a singleton, cephalic,
living fetus at or beyond 36 weeks of gestation, and who were in early labor (cervical
dilatation between 2 cm and 6 cm) were randomly assigned to either open or masked fetal
pulse oximetry. Further details of the methodology of the study have been described
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elsewhere. (15) All women enrolled in the trial (n=5341) were eligible for inclusion in the
secondary analysis except those women with missing information needed to determine the
customized fetal growth, and pregnancies complicated by major congenital malformations
(n=193). This study was deemed exempt from institutional review board review since the
data and samples were de-identified before the analysis was performed.
Growth Centile Calculations
Centile birthweight was determined for each individual pregnancy using ethnicity- and
gender-specific population (pop) norm, (6) and from a customized (cust) growth standard
developed by Gardosi et al.(12,13) The Gardosi customized growth model generates optimal
growth curves for individual pregnancies by taking into account maternal and fetal
characteristics: maternal weight (kg) and height (cm) at entry to care or pre-pregnancy,
ethnicity/race, parity (any birth after 20 weeks), and infant gender. (10,11) The actual
birthweight was compared with the optimal weight, and a measure of the percentage of
optimal growth was calculated using GROW (Gestation Related Optimal Weight) at
www.gestation.net. (13) Small for gestational age (SGA) was defined as ≤10th percentile by
either population (SGApop) or customized (SGAcust) method.
Outcomes
As this is a study in an intrapartum low risk cohort, our primary outcome was a composite
neonatal outcome that included neonatal death, intrapartum stillbirth, neonatal intensive care
unit (NICU) admission > 48 hours, 5-minute Apgar score < 4, umbilical artery blood pH <
7.0, seizures, or intubation in the delivery room. Secondary outcomes analyzed included
components of the composite outcome as well as low fetal oxygen saturation defined as fetal
oxygen saturation less than 30% for at least 2 consecutive minutes. Death, intrapartum
stillbirth, NICU admission > 48 hours, seizures and intubation in the delivery room were not
frequent enough to warrant separate analysis as secondary outcomes. We also analyzed
NICU admission, cesarean delivery and placental abruption. Details about these selected
outcomes are described elsewhere. (15)
Statistical Analysis
Statistical analyses were performed using SAS statistical software (SAS Institute, Cary, NC)
and R (www.r-project.org). In the original trial, the fetal pulse oximeter did not influence
outcomes; therefore, the two study groups (oximeter and control) were combined into one
cohort for the current analysis. The odds ratios (ORs) with 95% confidence intervals (CIs)
for the various APOs were calculated for SGAcust and SGApop. The concordance between
presence or absence of SGA and presence or absence of APO was calculated for each norm
and APO. For each APO and norm, a case was concordant when SGA by that norm and that
particular APO were both present or both absent. Concordance was compared between the
population and customized norms for each APO using McNemar test. (16)
Since the continuous values of the population norms were not available to us, we used the
following approximation approach. After an Arc-Tan based transformation of birth weights
(ArcTan((weight/1000)2)*2/π), we calculated the corresponding continuous values of the
population norms using a simple approximation method based on the linear connection of
the 3rd, 10th, 50th and 90th percentiles provided by Alexander et al. (6) in the different
races, infant genders and gestational age groups. The ability of the customized and generated
population birthweight centiles to predict APOs was then compared using the receiver
operating characteristics curve (ROC) and the area under the curve (AUC, or c-statistic). For
this study, since we did not assume any prior knowledge of the association, we did not
specify the association direction (positive or negative) between an adverse outcome and
SGA but rather used a two-sided approach. To be predictive of an event, the AUC must be at
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least 0.5 and the 95% CI must not cross 0.5. The population and customized AUC’s for an
individual outcome were then compared using a nonparametric statistical method for
comparing AUC’s. (17) Two-sided p-values <0.05 were considered statistically significant
and no adjustments were made for multiple comparisons.
Results
5148 women and their children were included in the analysis. Five hundred eight (9.9%)
neonates were SGA by population norms (SGApop) and 584 (11.3%) were SGA by
customized norms (SGAcust) (Figure 1). Three hundred and ninety seven neonates were
SGA by both methods, 111 were SGA by population centiles only (i.e. not SGA by
customized), and 187 were SGA by customized norms only (i.e. not SGA by population)
(Figure 1). The baseline maternal and fetal characteristics of the SGApop and SGAcust
neonates, compared with those of neonates not SGA by either norm, are summarized in
Table 1. Only 27 (3.9%) infants born SGA by either norm (n=695) developed the primary
neonatal outcome.
The associations between SGApop and SGAcust with APO and the incidence of APO in the
different groups are summarized in Figure 2. Only SGApop was associated with a
significant increase in the composite neonatal outcome (OR 1.59, 95%CI 1.02 – 2.48,
p=0.038), NICU admission (OR 1.71, 95%CI 1.20 – 2.43; p =0.002) and low fetal oxygen
saturation (OR 1.25, 95%CI 1.03 – 1.51; p=0.024); while both SGApop and SGAcust were
significantly associated with a 5-minute Apgar score < 4 (for SGApop, OR 4.59, 95%CI
1.14 – 18.4, p=0.018; for SGAcust, OR 6.29, 95%CI 1.68 – 23.5, p=0.002). Neither
SGAcust nor SGApop was associated with placental abruption or cord pH < 7.0. The odds
of CD were reduced in both groups, but was only significant in the SGApop group (OR
0.75, 95%CI 0.60 – 0.93; p=0.010).
The proportions of agreement between the APOs and either SGApop or SGAcust ranged
between 66% and 90% (Table 2). SGApop had significantly higher proportions of
agreement (i.e. higher proportions of correct associations between SGA status and the
outcome, as well as non-SGA status and the absence of the outcome) than SGAcust for all
outcomes except for CD for which the difference in agreement was not statistically
significant (Table 2).
Table 3 summarizes the AUC (and 95 % CI) of the ROC curve for prediction of APO by
population and customized norms. In general, the ability to predict adverse outcomes was
poor as 12 out of the 14 ROC’s had AUC’s less than 0.6. No significant differences between
methods were noted for any of the AUCs (Table 3).
Discussion
In an intrapartum cohort, neither customized nor normalized population norms identify
neonates at risk of adverse outcomes related to smallness for gestational age. However, there
was an association between SGA and a composite adverse neonatal outcome when using a
population-based approach, but not when using a customized approach.
Our study is novel in that we used two approaches in analyzing the data: first, we analyzed
the association between neonates born ≤10th percentile and APO, and then we approximated
the continuous values of the population percentiles and compared the 2 norms using ROC
curves, which has not been done in the prior validation studies. It was also unique as we
attempted to externally validate the Gardosi customized model for the US population in an
intrapartum setting. Additional strengths of our study include the use of the same cohort of
patients to compare customized and population norms. This allowed us to control for
Costantine et al. Page 4













differences in potential confounders when using different cohorts, such as pregnancy dating
bias which is especially important. (18) In addition, the outcomes have been accurately
ascertained in the primary study.
This study, however, is limited by its sample size which is relatively smaller compared with
the one used to develop the coefficients for the US population (12), and which did not allow
us to compare outcomes between neonates who were SGA for one but not the other norm,
however that does not negate our since our sample is derived from a cohort of patients
deemed stable for vaginal delivery. In addition, this was basically a cohort of term
nulliparous women with a normal fetal heart rate tracing, enrolled in a multicenter trial and
delivering at university hospitals and therefore with expected low rate of adverse events
related to SGA. In fact the primary neonatal outcome developed only in 27 infants out of
695 born SGA by either norm (3.9%). This is not surprising as fetuses with suspected
significant growth restriction and pregnancy with evolving obstetrical complications were
excluded or may have been delivered by cesarean before labor for fetal or maternal
indications. Additional limitation is that women were being enrolled at the time of delivery,
and so pre-pregnancy weight may not be the most accurate and not as well collected.
Because only nulliparous women were included, the parity component of the customized
model was not applicable in this cohort. Moreover, it is important to note that the population
norm that we used is not typically used in clinical practice or most studies. The typical
norms either do not take into account any variables other than gestational age, or merely add
either infant gender or ethnicity. By including both in the norm we used, and by nullifying
the contribution of the parity variable, we limited our ability to detect differences in
performance between the 2 norms. This is different from prior studies that compared the
customized model to the more often used population norm which is not adjusted for gender
and ethnicity.
Our findings should not be used to dismiss the Gardosi model for the US population, as the
limitations of this study may explain some of the apparent discrepancy between our results
and those from other studies that demonstrated that SGAcust is superior than SGApop in
association with antepartum, intrapartum and neonatal complication. (9, 19–25) The
discrepancy regarding stillbirth with the internal validation of the US model (14) may be
explained by the fact that our data was limited only to intrapartum stillbirth. Moreover, 32.0
% (187 out of 584; Figure 1) of neonates in our cohort who were SGA by customized
standards were not classified as SGA by population norms, and these neonates have been
reported in previous studies to have higher risk of adverse outcomes. (9, 14) Conversely,
only 21.8 % (111 out of 508; Figure 1) of neonates determined to be SGA by population
standards were not detected as SGA by the customized approach, and these were found in
prior studies not to be associated with increased rates of neonatal complications. (9, 14)
In summary, a customized approach for fetal growth assessment did not perform better than
a normalized population approach that adjusts for ethnicity and infant gender, and neither
approach was adequate in predicting infants at risk of adverse outcomes related to SGA in
our cohort of low risk women. Further studies are necessary to determine if using ultrasound
based customized fetal weights as a standard measure improves neonatal and infant health
outcomes, and to investigate the utility of the customized model in predicting the long term
outcomes associated with growth restriction.
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distribution of neonates classified as small for gestational age (SGA) by the population
(SGApop, n=508) and the customized methods (SGAcust, n=584). The diagram also shows
the subgroups that are SGA by both methods (n=397) and SGA by population or customized
norms only (SGApop only, n=111 and SGAcust only, n=187)
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Odds and incidence of adverse perinatal and neonatal outcomes in SGA neonates by
population or customized norms categories compared with those not SGA.
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Table 1
Maternal and fetal characteristics of SGA neonates by population or customized standards, and those not SGA
by either.
Variable SGA by population (N=508) SGA by customized (N=584) Not SGA by either method (N=4453)
Maternal age (years) 23.2 (5.5) 23.3 (5.5) 23.6 (5.5)
BMI (at entry to care) (kg/m2) 24.5 (5.9) 27.4 (7.3) 25.4 (6.0)
Ethnicity
 Caucasian 168 (33.1) 238 (40.7) 1345 (30.2)
 African American 260 (51.2) 289 (49.5) 2374 (53.3)
 Hispanic 65 (12.8) 50 (8.6) 641 (14.4)
 Other 15 (2.9) 7 (1.2) 93 (2.1)
GA at delivery (weeks) 39.4 (1.2) 39.9 (1.4) 39.8 (1.3)
Parity
 1 508 (100) 584 (100) 4453 (100)
 >1 0 (0) 0 (0) 0 (0)
Birth weight (grams) 2632.5 (253.5) 2728.6 (311.5) 3463.0 (403.2)
Male gender 271 (53.4) 305 (52.2) 2333 (52.4)
Data are reported as mean (SD), or n (%)
SGA = small for gestational age, BMI = body mass index, GA = gestational age
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Table 2
Proportion of agreement between SGA status defined as < 10th percentile and outcome
SGApop % SGAcust % P *
Composite neonatal outcome ¶ 87.9 86.3 <0.0001
Low fetal O2 saturation § 66.4 65.6 0.021
5-min Apgar < 4 90.1 88.6 <0.0001
NICU admission 86.6 85.1 <0.0001
Cord blood pH < 7.0 89.8 88.3 <0.0001
Cesarean delivery 67.6 67.2 0.247
Placental abruption 90.0 88.5 <0.0001
SGApop = SGA by population norm; SGAcust = SGA by customized norm
*
P using McNemar test for difference to test the agreement between SGApop & SGAcust for the outcome
¶
 Composite neonatal outcome if any of the following: 5-minute Apgar score < 4, an umbilical-artery blood pH <7.0, seizures, intubation in the
delivery room, stillbirth, neonatal death, or admission to the NICU for more than 48 hour
§
 Low fetal oxygen saturation: less than 30% for at least 2 consecutive minutes
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Table 3
Area under (AUC) the receiver operating characteristics (ROC) curve for prediction of adverse perinatal and






Composite neonatal outcome ¶ 0.56 (0.52–0.61) 0.56 (0.51–0.60) 0.671 Both predictive, not statistically
different
Low fetal O2 saturation § 0.49 (0.48–0.51) 0.48 (0.47–0.50) 0.079 Neither predictive
5-min Apgar < 4 0.73 (0.58–0.88) 0.69 (0.53–0.86) 0.488 Both predictive, not statistically
different
NICU admission 0.54 (0.50–0.58) 0.55 (0.52–0.59) 0.329 Both predictive, not statistically
different
Cord blood pH < 7.0 0.51 (0.40–0.62) 0.43 (0.32–0.53) 0.042 Neither predictive
Cesarean delivery 0.54 (0.52–0.56) 0.53 (0.51–0.55) 0.280 Both predictive, not statistically
different
Placental abruption 0.51 (0.32–0.70) 0.57 (0.39–0.75) 0.401 Neither predictive
*
P for two-sided, pair-wise ROC comparison. (AUC with CI crossing 0.5 was not considered for the comparison). Bold for AUC > 0.5 and 95% CI
does not cross 0.5
¶
 Composite neonatal outcome if any of the following: 5-minute Apgar score < 4, an umbilical-artery blood pH <7.0, seizures, intubation in the
delivery room, stillbirth, neonatal death, or admission to the NICU for more than 48 hour
§
 Low fetal oxygen saturation: less than 30% for at least 2 consecutive minutes
¥
 After an Arc-Tan based transformation of birth weights (ArcTan((weight/1000)2)*2/π), we calculated the corresponding continuous values of the
population norms using a simple approximation method based on the linear connection of the 3rd, 10th, 50th and 90th percentiles provided by
Alexander et al. (6) in the different races, infant genders and gestational age groups.
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